Association between metformin medication, genetic variation and prostate cancer risk.
Min Joon LeeViranda H JayalathWei XuLin LuStephen J FreedlandNeil E FleshnerGirish S KulkarniAntonio FinelliTheodorus H Van der KwastRobert J HamiltonPublished in: Prostate cancer and prostatic diseases (2020)
In our cohort, metformin use was associated with increased risk of being diagnosed with prostate cancer. While SNPs involved in metformin metabolism did not have modifying effects on the association with disease risk, one intronic and one intergenic SNP from the GWAS study did, and these require further study.